Early onset ovarian insufficiency
Conditions
Interventions
control group:Dong'e Ejiao mimetic (powder): 9g / bag, 1 bag / time, 1 time / day, boiled water
experimental group:Dong'e Ejiao (powder): 9g / bag, 1 bag / time, 1 time / day, boiled water
Sponsors
Beijing Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Consistent with the diagnosis of early-onset ovarian insufficiency; (2) In accordance with the syndrome differentiation of blood deficiency; (3) At baseline, serum follicle stimulating hormone (FSH): 25-40u / L; (4) Voluntarily participate in this clinical trial, give informed consent and sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Age 1mg and didroxyprogesterone > 10mg); (6) Have received non hormonal drugs and non drug treatments (such as acupuncture, external application, enema, etc.) that have therapeutic effects on the disease in the past 1 month; (7) ALT or AST = 1.5 times the upper limit of normal reference value or SCR > the upper limit of normal reference value; (8) Mental retardation or psychosis or neurosis; (9) Complicated with serious primary diseases such as heart, brain, lung, liver, kidney, endocrine, nervous system and hematopoietic system; (10) Combined with BI-RADS grade > 3 and uterine leiomyoma > 3cm; (11) There are symptoms of nausea, abdominal distension, loose stools, yellow and greasy tongue coating; (12) There are contraindications to periodic treatment with fenmutone hormone, known or suspected history of breast cancer, known or suspected estrogen dependent tumor (such as endometrial cancer), unexplained genital bleeding, untreated endometrial hyperplasia, previous idiopathic or existing venous thromboembolism (deep venous embolism, pulmonary embolism), active or recent arterial thromboembolic disease (such as angina pectoris, myocardial infarction), history of meningioma Acute liver disease or history of liver disease, failure to restore normal liver function indicators, known hypersensitivity to active components of fenbutone or any excipients, porphyria; (13) Pregnant and lactating women or within half a year have family planning; (14) Suspected or actual history of alcohol and drug abuse; (15) Known or suspected history of allergy to the ingredients and excipients of the test drug; (16) Participated in other clinical trials in the past 3 months; (17) The investigator considers it inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| FSH; | — |
Secondary
| Measure | Time frame |
|---|---|
| AMH;Transvaginal ultrasound;Five items of sex hormone;AMH;Kupperman;AMH; | — |
Countries
China
Contacts
Public ContactXiuxiang Teng
Outcome results
None listed